New hope for elderly myeloma patients: drug combo aims to deepen remission without transplant

This phase 3 study tests whether adding the drug isatuximab to a standard two-drug regimen (lenalidomide and dexamethasone) works better with or without a third drug (bortezomib) for older adults (65-79) newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The main goal is to see how many patients achieve a very deep remission (minimal residual disease negative) at 18 months. About 270 participants will be enrolled, and the study is active but no longer recruiting.